News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioInvent (BOVNF) Extends Collaboration for the Discovery and Development of Therapeutic Antibodies With Mitsubishi Tanabe Pharma Corporation


7/2/2013 8:05:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Lund, Sweden – 2 July, 2013 – BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent's n-CoDeR® library. Under the terms of the extension, Mitsubishi Tanabe will continue to have access to BioInvent's discovery and development technology platform for a further two years and can develop up to eight antibody programmes.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES